Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Lowered to Neutral at Piper Sandler

Piper Sandler downgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from an overweight rating to a neutral rating in a research report released on Wednesday morning, MarketBeat.com reports. The firm currently has $36.00 price objective on the specialty pharmaceutical company’s stock, down from their previous price objective of $41.00.

Separately, StockNews.com raised Supernus Pharmaceuticals from a buy rating to a strong-buy rating in a research report on Wednesday, August 7th.

Supernus Pharmaceuticals Stock Performance

SUPN stock opened at $31.11 on Wednesday. The firm has a market capitalization of $1.71 billion, a price-to-earnings ratio of -107.28 and a beta of 0.88. The firm has a 50 day moving average price of $31.69 and a 200-day moving average price of $30.41. Supernus Pharmaceuticals has a 52-week low of $21.99 and a 52-week high of $35.44.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $0.36 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.39 by ($0.03). The company had revenue of $168.30 million for the quarter, compared to analysts’ expectations of $148.83 million. Supernus Pharmaceuticals had a net margin of 0.83% and a return on equity of 0.56%. The firm’s quarterly revenue was up 24.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.02) EPS. As a group, sell-side analysts forecast that Supernus Pharmaceuticals will post 1.56 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Congress Wealth Management LLC DE boosted its stake in shares of Supernus Pharmaceuticals by 37.8% in the first quarter. Congress Wealth Management LLC DE now owns 177,801 shares of the specialty pharmaceutical company’s stock worth $6,065,000 after acquiring an additional 48,750 shares during the period. Sei Investments Co. grew its holdings in Supernus Pharmaceuticals by 24.4% during the 1st quarter. Sei Investments Co. now owns 330,580 shares of the specialty pharmaceutical company’s stock valued at $11,276,000 after buying an additional 64,752 shares in the last quarter. Russell Investments Group Ltd. raised its position in shares of Supernus Pharmaceuticals by 205.2% during the first quarter. Russell Investments Group Ltd. now owns 97,988 shares of the specialty pharmaceutical company’s stock valued at $3,342,000 after buying an additional 65,880 shares during the last quarter. Schroder Investment Management Group purchased a new position in shares of Supernus Pharmaceuticals in the fourth quarter worth $15,685,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Supernus Pharmaceuticals by 2.3% in the fourth quarter. Vanguard Group Inc. now owns 6,214,731 shares of the specialty pharmaceutical company’s stock worth $179,854,000 after buying an additional 142,551 shares in the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.